Polar Capital Healthcare Opportunities breaches 10% exposure limit after Danish pharma firm soars

Zealand Pharma A/S

The Polar Capital Healthcare Opportunities fund has breached the 10% holding limit for UCITS funds, as its top holding swelled to more than 12% of the vehicle thanks to a rally in weight loss investments.

The fund's exposure to Danish pharmaceutical firm Zealand Pharma A/S hit 12.1%, according to its February factsheet, surpassing the 10% limit imposed on UCITS vehicles. Four Graphs explaining silver Zealand Pharma is involved in the production and design of diabetes and obesity medications, a corner of the healthcare market which has seen a huge surge in investment in the wake of Novo Nordisk's Ozempic medication becoming a cult product for weight loss. The company's shares had historically traded at around 200 DKK (£22.92) per share, but last month it experienc...